Biocompatibility of Medical Devices - A Review

Ramya Shree Gangadhar¹, Balamuralidhara V.² Rajeshwari S.R.³

^{1, 2, 3} Department of Pharmaceutics, JSS College of Pharmacy,
JSS Academy of Higher Education & Research, Mysuru, Karnataka, India.

ABSTRACT

BACKGROUND

Biomaterial is defined as "any substance or combination of medicine, artificial or natural origin, which can be used at any time, in whole or part by a system that controls, adds to, or restores any tissue, organ or function". ISO 10993-1: 2018 standard defines bio compliance law as "the ability of a medical device or tool to perform a selected program with the acceptable response of experts".

Incompatible factors cause chemical reactions in patients, with little or no side effects. The body can respond in a sort of way after the installation of medical devices, so testing and improvement is important here. Therefore, testing and improvement in this field are important.

Biocompatibility is required for any significant use of components or materials in medical devices. Inconsistent factors create negative biological responses in patients, which may have serious consequences. Biomaterials are substances utilized in medical devices, especially in applications where the device is touched, temporarily embedded, or permanently implanted within the body. Because of the significant impact of biocompatibility, many countries have imposed regulations on medical device manufacturers to meet biocompatibility specifications.

Here is a brief explanation about the biocompatibility and incompatibility parameters of medical devices with a human body and its need for biocompatibility of medical devices with the human body. Medical devices have improved doctors' ability to diagnose and treat disease, which has led to significant improvements in health and quality of life. Thus, medical devices are prone to various incompatibility issues and procedures that affect the biological environment must be followed.

KEY WORDS

Biocompatibility, Material Interactions, Sterilization, Medical devices, Biocompatibility Testing, Incompatibility Factors.

Corresponding Author:

Dr. V. Balamuralidhara,
Assistant professor,
Department of Pharmaceutics,
JSS College of Pharmacy,
JSS Academy of Higher Education &
Research, Mysuru, Karnataka, India.
E-mail: baligowda@hotmail.com

DOI: 10.14260/jemds/2021/641

How to Cite This Article:

Gangadhar RS, Balamuralidhara V. S.R.
Rajeshwari. Biocompatibility of medical
devices - a review. J Evolution Med Dent Sci
2021;10(36):3152-3158, DOI:
10.14260/jemds/2021/641

Submission 18-06-2021,
Peer Review 11-08-2021,
Acceptance 18-08-2021,
Published 06-09-2021.

Copyright © 2021 Ramya Shree
Gangadhar et al. This is an open access
article distributed under Creative
Commons Attribution License [Attribution
4.0 International (CC BY 4.0)]

BACKGROUND

The main purpose of this article is to provide a general understanding of the importance of biological compatibility in the development and installation of medical devices. It serves as a basis for a set of ISO 10993 standards for testing biological frameworks. The following risks may arise from the use of materials that do not meet the standards of biocompatibility for targeted use;

- a) Short term effects (e.g., severe toxicity, inflammation of the skin, eye and mucosal glands, sensitivity, haemolytic anaemia).
- b) Long term or specific toxic effects (e.g., carcinogenicity and teratogenicity).¹

The presence or absence of biocompatibility compliance in a medical device is indicated by a series of laboratory tests, the size of which is determined by the intended use of the product. Tests are performed in vitro and in vivo, in both laboratory organisms and independent cell structures. The results are usually made by professional laboratories and are closely related to a specific product. At present, it is one of the "compulsory" tests conducted as part of the risk management process, in accordance with professional guidelines, in the context of monitoring and evaluation. They are part of the documentation of compliance testing procedures. It is still a time-consuming and expensive task.¹

Materials and Methodology

The ability of the system (medical tool) to perform the required function (associated with the provision of health care) without significant and short-term adverse clinical manifestations and long-term reputation is known as biocompatibility. It can be the tolerance of technology and products that are environmentally friendly. Cytotoxic, toxicological, and allergen responses, as well as carcinogenic, teratogenic or mutagenic effects and the ability to influence infectious processes, should all be considered when evaluating such interactions. In addition, there is the issue of biodegradation, coagulation, formation of inflammatory responses, and the possible release of potentially harmful sub-micron particles.

Both the biophysical and biochemical processes that take place in such a complex connection, as well as the biological response to these processes, must be identified and evaluated. All changes in the physical and chemical properties of the interface are also important (e.g., changes in the structure of its free energy and energy base, level and environment of corrosion, natural decay, etc.).²

Any equipment intended for use as a component or use in medical devices must be compatible with two components. Uncertainty factors create chemical reactions in patients and health care providers, which can have a variety of consequences. Manufacturers now have access to the required standards and specifications to meet the requirements of compliance due to international law. Such regulations are constantly evolving to represent improvements in diagnostic procedures and harmonized practices between national regulatory agencies responsible for the medical equipment industry.¹

A biomaterial is defined as "any substance (other than drug) or a combination of substances, synthetic or natural in

origin, which may be used at any time, in whole or in part for a system that treats, adds, or restores any tissue, organ, or function" by the National Institute of Health Consensus Development Conference in November 1982.³

The overall purpose of this discussion is to provide a general indicator of the quality of biological compatibility as a requirement in device design and treatment. It also serves as the starting point for a set of ISO 10993 standards for the biological testing of medical devices.

The physical or physical condition in which the device is to be used, and the duration of use, defines the human - interface.

A Primer on the ISO 10993 Standards

ISO 10993 is a collection of guidelines that enable medical device manufacturers to identify and perform various environmental tests. This set of standards is the product of efforts to integrate and harmonize a wide range of global and national standards as well as guidelines related to the biological testing of a medical device.

ISO 10993 - 1, the first part of the standard, provides guidelines and instructions for the "collection of tests that allow for the testing of biological responses related to the protection of devices and medical devices."¹

Haematoxylin compounds - Eosin-stained paraffin is a popular way to test injections or implants. This is good for diagnosing malignant tissue formation and tissue reactions, including inflammation. With the discovery of complex biological changes, various advanced pathogens and immune histochemical mechanisms have been identified. It is important to understand the limitations of strategies.

Both in vitro and in vivo studies will benefit from molecular probes, such as antibody-based testing of a pro-inflammatory molecule released or seeking improvement in gene expression linked to tissue damage. Toxicogenomic methods used to accelerate drug development may also be helpful.⁴

Results

The main outcome of this article is to understand the incompatibility factors of medical devices, when they are being introduced into the human body and have a brief knowledge about the medical device interactions with tissues.

DISCUSSION

The remaining standards in the ISO 10993 family of standards consist of the following parts -

- Section 2: Conditions for animal protection
- Section 3: Genotoxic, carcinogenic, and reproductive toxicity tests
- Section 4: Choosing tests for blood connections
- Section 5: Cytotoxicity tests: in vitro methods
- Section 6: Post-implantation tests for local effects
- Section 7: Ethylene oxide sterilisation residuals
- Section 9: Methodology for identifying and quantifying possible degradation products
- Section 10: Annoyance and sensitization tests

- Section 11: Systemic Toxicity Tests
- Section 12: Preparation of samples and reference materials
- Section 13: Polymer degradation products identification and quantification
- Section 14: Degradation products from ceramic identification and quantification
- Section 15: Metal and alloy degradation products identification and quantification
- Section 16: Creation of a toxicokinetic sample for degradation products and leachable materials.¹

ISO 10993 Family	Standards Biological Evaluation of Medical Devices
ISO 10993 - 1	Risk management process evaluation and testing
ISO 10993 - 2	Animal welfare requirements
ISO 10993 - 3	Genotoxicity, carcinogenicity, end reproductive toxicity tests
ISO 10993 - 4	Test interactions with blood selection
ISO 10993 - 5	Tests for in vitro cytotoxicity
ISO 10993 - 6	Tests for local effects after implantation
ISO 10993 - 7	Ethylene oxide sterilization residuals
ISO 10993 - 9	Identification and quantification of potential degradation products
ISO 10993 - 10	Tests for irritation and skin sensitization
ISO 10993 - 11	Tests for systemic toxicity
ISO 10993 - 12	Sample preparations and reference materials
ISO 10993 - 13	Identification of degradation materials from polymeric medical devices
ISO 10993 - 14	Identification of degradation materials from ceramics
ISO 10993 - 15	Identification of degradation materials from metals
ISO 10993 - 16	Toxicokinetics of degradation products
ISO 10993 - 17	Allowable limits for leachable substance establishment
ISO 10993 - 18	Chemical characterisation of materials
ISO 10993 - 19 (TS)	Physicochemical and morphological characterisation of materials
ISO 10993 - 20 (TS)	Immunotoxicological testing of medical devices
ISO 10993 - 22 (TR)	Guidance on nanomaterials
ISO 10993 - 33 (TR)	Guidance on genotoxicity tests

Table 1. ISO 10993 Family Subsections.¹

ISO 10993 - 1 defines a system for the separation of medical devices that interact with patients based on the intended operation. Medical devices are divided into the following categories using this classification system - Devices that contact the surface (i.e., devices which contact intact skin, mucosal membranes and breached or compromised devices)

External communicators (i.e., devices which contact the blood path indirectly, tissue, bone or dentin or circulating blood.) Implantable medical devices (devices that contact tissue or bone or blood as an implant)

Biocompatibility Compatibility Tests

To evaluate compliance, in vitro and in vivo tests are used. In vitro data provide shaky estimates of the ability to function in the presence of the right cell types. This can be accomplished using a series of methods, DNA measurements, cell growth measurements, and dye-derived cell beam analysis. In vivo studies are needed to fully understand biocompatibility compatibility. Conversely, we conclude that in vitro cell models closely resemble their in vivo counterparts.

Materials Used for Medical Devices

Metals, polymers, and clay are the three types of materials used in the installation and planting of a product.

Metals have metal bonds, pottery has ionic bonds, and polymers have covalent bonds, and each of these groups has several layers. Stainless steels and alloys are incorporated

into metals, glass, glass-ceramics, and carbon added to pottery; and thermosets, thermoplastics, elastomers, and fabrics are embedded in polymer materials.

Most inputs work best when the biomaterials used in their construction are chemical-free and organic; there is no biological, let alone medical, practice in these devices to be followed.

For load-bearing equipment, metals are the most widely used. This includes anything from basic ropes and screws to apartments for repairing fractures and integrated joints (prostheses) at the waist, knees, shoulders, and ankles, among other areas. Metal implants are also used for maxillofacial surgery, heart surgery, and dental implants, in addition to bones. Stainless steel, cobalt-base alloys, titanium pure and titanium alloys, and a few other metals are the most widely used in medical device applications.⁴

Figure 1. Incompatibility Assessment Parameters.⁴

Material Interactions

When a technical device interacts with a natural ("living") environment (reaction), a very small inlet layer is formed, consisting of water molecules with irregular shapes (usually from nature), where a protein layer is released on the surface of the material. The physical and chemical properties of this visible component (including those found) determine its existence, and tissue structures are relegated to the "level" of biological balance. Denaturation is a consistent process that involves the disintegration of amino acid peptide bonds, loss of native structure, loss of soil melting, and the formation of pathogens.²

The flexible membrane, such as a dialyser used to treat kidney failure, is an example. Due to the scope and severity of this treatment, this is a well-developed condition, given the fact that clinical results are undeniable but difficult to confirm. As the membrane interacts with the blood, the monocytes are produced from proteins that regenerate parts of the immune system. Systemic inflammatory response syndrome is caused by the membrane content. The development of pro-inflammatory cytokines (e.g., IL - 1, TNF, IL - 8) and anti-inflammatory cytokines is a hallmark of this phase (IL - 10).

- Release of active C3a and C5a anaphylatoxin;
- High concentration is achieved after 15 minutes of treatment;
- Development of membranolytic complex C5a - C9, and activation of neutrophils and monocytes;

- Complex formation of C5a - C9 persists during treatment and lasts for several hours after discontinuation of the treatment.

Anaphylactic reactions (especially shock), hypotensive conditions, pyrogenic reactions, smooth muscle smoothness, and amyloid-like formation are all important clinical outcomes for completeness. Such health problems include amyloidosis, joint problems, and pulmonary fibrosis, among others.²

Biomaterials Aren't Harmless

There has been a great deal of interest in creating objects that turn the environment around. Similarly, researchers are increasingly realizing that even things that enter the body, such as those used as barriers or drug delivery systems, are not just "innocent spectators" in their places. Cross-linked hyaluronic acid gel, on the other hand, may prevent adhesion formation by causing tissue plasminogen removal, which has been shown to reduce adhesion formation. In addition, microparticulate formation is not inert. The inflammatory response they can cause, because it is exactly what was intended to kill the immune system, is one of the most obvious ways to affect their environment. They can affect tissue reactions to drugs, as will be seen by going down. The natural effects of nanoparticles are unknown, but given their high potential for cell penetration, they can be valuable.

Directly Reducing Tissue Reaction

Altering tissue reactions with therapies and alternatives can increase biocompatibility interactions. Anti-inflammatory chemicals can be put into the system to reduce inflammation around. Adding glucocorticoid receptor agonist budesonide to polysaccharide-based hydrogels, as well as the incorporation of dexamethasone (another glucocorticoid agonist) into the hydrogel spine, significantly reduced inflammation cell penetration.

Although it does not directly cure inflammation, some medications can have similar effects. The addition of a tissue plasminogen activator to hydrogels will alter the balance between clot formation and tissue destruction (fibrinolysis), preventing peritoneal adhesion. PEGylation (ethylene glycol), which reduces particle contact with the reticuloendothelial system and thus improves circulation time, is the only facial modification that contributes significantly to drug delivery.⁴

IMPLANTABLE DEVICE REQUIREMENTS

Mechanical Characteristics

The structural features used in medical devices that can be included are elasticity, yield strength, durability, penetration, high strength, fatigue, stiffness, and wear resistance.

Efficient Yields

The carrying capacity of the input is determined by the strength of its production. For example, in total joint replacement surgery (TJR), where the load-bearing capacity is significant, the energy value of the alloy product should be high enough. For this reason, bone alloys should have a high yielding potential during ductile (defined by the percentage

of expansion or reduction of the local percentage in the standard strength test)

Modulus Elastic

The extremely high modulus insertion compared to bone remains a source of concern. Long-term data suggests that insufficient load transfer from implants to a nearby repair bone can lead to bone recovery and loosening of the next implant device. When a load of stiffness / compression or bending where the living bone is found decreases, bone stiffness, bone loss, and osteoporosis are seen. This is known as a stress-relieving effect and is due to differences in flexibility and durability, which are determined in part by the flexible module difference between natural and synthetic materials.

Tiredness

When designing an alloy, the flexible resistance to metal inserts is also a source of concern. During physical activity, bone grafting is subjected to rotating temperatures, leading to changes in the plasticity of the small pressure points caused by a notch and microstructural inhomogeneities. Pressure / congestion, bending, straining, and rotating bending fat are all common fatigue tests.

Biocompatibility and Corrosion

The reaction to the visual link between the installation and the physical environment determines the level of performance of the installation. The pull is obtained using a protective film over the artificial inserts made of steel and alloys. The film prevents corrosion and holds the output of the current flow and corrosion to a minimum, that is, all implants can sometimes be damaged due to the strong body structure. The only way to prevent corrosion from being damaged is to choose an alloy with more advanced properties, which can be obtained by adding environmentally friendly mixing materials, textures, and stains.

The Process of Sterilisation

Infection is a major problem with artificial insemination, and the fact that low-virulence species are often found to be pathogenic when polluting the bioimplant adds to the complexity. In addition, little is known about how the synthetic substance affects the host's immune response or the inflammatory response the prosthesis encounters. Any factors that contribute to the pathogenesis of such an infection and the incidence of the infection in the shape and function of the object, its location, the length of time it has been used, and the patient's condition. The same implants can be found on different parts of the body.⁵

Chemistry of biocompatibility: Biomaterials are usually derived from materials used in other industries with the desired mechanical properties but are not designed to interact with tissue or blood. The lack of understanding of tissue and tissue interactions, and where chemical interactions should be tested, hindered attempts to construct highly inconsistent substances. The problem is compounded by the fact that, bio compact interactions are much more complex than simple interactions between a single substance and a single cell type, including detoxification products, different drugs and manager effects, and different cell types.⁴

Implantable Devices and Biological Responses

Inflammatory Reaction

The inflammatory response is caused by tissue damage due to the insertion of the device and the continued presence of the device in the body. When tissues are damaged as a result of systemic implantation, a complex sequence of events triggers a wound healing response. Acute inflammation, chronic inflammation, and granulomatous tissue formation are the three major stages of this phase. This response is primarily a hemodynamic energy activity and is thought to be a host effort to reduce the shocking agent and reduce the concentration of harmful molecules. Chronic inflammation develops as a result of recurrent inflammation, such as the presence of an external substance.

Foreign Body Reaction

External immune reactions occur when biomaterial is injected into the body. The magnitude of this reaction is determined by the properties of the device, including

1. Form,
2. Scale,
3. Surface chemistry and size,
4. Geometry,
5. Morphology and porosity,
6. Composition,
7. Reproductive issues,
8. Contact length,
9. Damage.

After implantation, a polymer blood interface was formed, creating an unspecified absorption of blood and tissue over the wire. Immune and inflammatory cells including monocytes, leukocytes, and platelets intervene after the intricate intrusion of proteins to protect the body from foreign matter. A vascular, collagenous fibrous capsule is used, usually 50 - 200 mm thick to wrap around the wall at the end of the external body response. The embedded system is contained in this fibrous wall, which makes it unable to communicate with the surrounding tissues.⁶

Testing for Biocompatibility

It is widely acknowledged that the term "biocompatibility" refers not only to the biomaterial deficiency of cytotoxicity but also to the bioactivation of the substance, which allows it to facilitate the interaction of biomaterial cells in the context of a particular environment and organ when used. To test local and systemic effects on cultured cells, tissue components, and the rest of the body, the compatibility tests on the implanted device require complex in vitro and in vivo tests. Methods focused on the testing of cytotoxicity, mutagenesis / carcinogenesis, and biocompatibility and bio functionality of materials are used to determine the biocompatibility and bio functionality compliance.

In-vivo biocompatibility test of implantable glucose sensors for diabetes control was developed by Koschwanetz and colleagues. During the procedure, exudates are released from the cage and analysed for the presence of inflammatory cells, enzyme fluid, and cell interactions such as fibrous encapsulation and infection. This method allows for a series of fluid tests around the patient.

A different approach is to use a tissue chamber device. The back of the animal is permanently attached to lightweight aluminium or titanium frame. The inserted unit, like the

biosensor, is housed in a leather cage, enclosed between two plates with stainless steel. This method is useful in determining the status of a sensor. By removing the skin and covering the area with glass, real-time detection of the system is possible.

5.1 Ames testing is a widely used tool to determine mutagenesis / carcinogenesis. This method uses a type of *Salmonella typhimurium* with a malignant (mutant) characteristic to identify mutations in the body's immune system. From the core of the culture, this bacterium cannot synthesize the amino acid histidine.

Other mutations (including these) can be reversed by background reversal, in which the gene reactivates after exposure to mutagenicity. These changes can develop in a non - histidine environment.

The number of recurrent colonies, mutagenesis, and carcinogenesis induced by factors can be estimated. To evaluate the function of cell bio functionality, various parameters are used, such as cell adhesion, distribution, and biosynthetic activity.⁶

Toxicological Risk Assessment

Risk assessment is a systematic study of adverse health effects from exposure to chemicals or hazardous substances. Risk is defined as the potential for adverse outcomes as a function of exposure to harmful agents and forces. Integration of relevant scientific and quality data is required for risk assessment.

The four components of a risk assessment are:

Risk Identification

An assessment of the basic health risk of an item. The chemical ability to cause lung cancer or liver damage, for example, is exemplary.

- Dose Analysis-response: determining the amount of agent needed to cause toxic reactions, as well as dose estimates that will have side effects or minor side effects.
- Exposure test: Agent analysis of the agent, form, size, and contact time. Identifying the most important means of expression is an important first step.
- Risk description: evaluation and execution of relevant data from threat, volume response, and exposure studies.⁷

Regulatory Guidance

In conducting a toxic risk assessment, the four ISO compliance standards listed below provide guidance and information: ISO 14971: 2007 is a standard that specifies how to apply a variety of contexts. 17 Appendix I, 'Guidelines for the Biological Risk Assessment Process,' provides guidance on the potential biological hazards caused by chemical components. To measure risk, there are three major factors to consider, in terms of this level of consensus -

1. Hazardous chemistry
2. Environmental protection data
3. Previous use of this information

Table 1 - ISO 10993 standards for biocompatibility of medical devices.⁶

Problems Caused by Implantable Devices: Challenges to Overcome-

1. Due to fibrosis encapsulation, the glucose sensor's functionality has been lost.
2. Restenosis following stent placement
3. Implantable Device Calcification.⁶

Why Should Cytotoxicity be Verified on a Device?

Ignoring biocompatibility studies, especially in-vitro cytotoxicity, has a long and positive history. This is an example from a time when there were no established guidelines for monitoring the environmental effects of a device. In the early 1980s, urinary organs appeared in a group of male patients who had open-heart surgery. Most of these patients had latex wrists, according to an additional study. In uroepithelial cells, latex was later found to be cytotoxic.⁸

Fibrosis Encapsulation Impairs Glucose Sensor Function

In patients with diabetes mellitus, a high-dose insulin system should be monitored. On the other hand, the discomfort and pain of such vigilance reduce patient compliance. Glucose sensors that can be installed are a promising solution to this issue, and many researchers have been working on them recently. Implanted nerves and / or density instability. Many studies have shown that glucose sensors lose their function in the same way. Deliberate glucose sensors cause tissue damage, and the surface of the device meets the body for a long time, stimulating and supporting the external body's response.⁶

Following Stent Implantation, There is a Risk of Restenosis.

Patients undergoing percutaneous coronary revascularization were fitted with coronary stents. Even though the incidence of respiratory incontinence after coronary stent insertion is lower than that after balloon angioplasty, stent restenosis remains a major problem. The stent protrudes between the endovascular tissues and connects directly to the vessel wall. This can damage endothelial vascular tissue, triggering an inflammatory response that can lead to increased neointimal and restenosis. The magnitude and duration of local inflammation determine the chances of rest.⁹

Implantable Device Calcification

The calculation refers to the composition of the mineral calcium in the included devices. In vivo, the computation can significantly affect system performance. It is important to develop strategies to reduce the calculation to keep the heart valves working properly. Preventing biomaterial inclusion counts has been the subject of further study. There are two different approaches to this study. Another combination of device installation and drug delivery system that uses drugs to assist with the biocompatibility of the device. A hydrogel coating has been made that provides.¹⁰

When implants such as glucose biosensors are implanted, the external body reaction causes inflammation and fibrosis without any precautionary measures. The substances used in these sensors will help to reduce the body's reaction, and the

incompatible substances have come a long way in recent years. The use of an outer cover that measures body tissue has been shown to reduce adverse reactions while maintaining sensory function. Hydrogel coverings can help with this.¹¹

The most effective anti-inflammatory and fibrosis are published at the local level. Hydrogel coating has been developed that allows anti-inflammatory drugs and other agents to be released slowly while enabling the rapid spread of analytic with sensory hydrogel. The exclusion of growth factors in the sensor area has been studied to create vascular growth and ultimately available analytics. These efforts to construct glucose-related biosensors are expected to contribute to the development of long-term biosensors that will be fully invested in soon.⁶

CONCLUSIONS

Medical equipment has always been an important part of modern medicine. Medical advances in implanted devices have led to significant improvements in people's health, including cosmetic treatments, dentists, facials, and cardiac devices. Medical devices have improved doctors' ability to diagnose and treat disease, which has led to significant improvements in health and quality of life. Manufacturers must ensure that the biocompatibility requirements are met fairly and efficiently so that the device can be used in a health care setting. ISO 10993 is a collection of overseas standards that provide guidance and instructions to assist manufacturers in selecting and implementing a device to ensure device performance equity. Thus, the medical devices are prone to various incompatibility issues as discussed above and procedures, actions that affect the biological environment must be strictly followed.

Financial or other competing interests: None.

Disclosure forms provided by the authors are available with the full text of this article at jemds.com.

I acknowledge Dr V Balamuralidhara, who helped me in proofreading the article, also helped me in writing this review article with good scientific merit and language support. This work was carried out in collaboration between the three authors. The authors Ramya Shree G, Dr Balamuralidhara V, Rajeshwari S R, who carried out the literature search, performed the statistical analysis, carried out the work and wrote the article. All together read and approved this final manuscript.

REFERENCES

- [1] Lam V. Biocompatibility of medical devices: an introduction. Evaluation 2001;1-7. http://www.service.hkpc.org/hkiemat/previous/2008/mastec03_notes/VLAM.PDF
- [2] Augustynek M, Cihak J, Vilimek D, et al. Biocompatibility of medical devices and their risks. Eur Workshop on Visual Information Processing (EUVIP) 2019;2019:228-31. <https://>

- www.researchgate.net/publication/338368280_Biocompatibility_of_Medical_Devices_and_Their_Risks
- [3] Helmus MN, Gibbons DF, Cebon D. Biocompatibility: meeting a key functional requirement of next - generation medical devices. *Toxicol Pathol* 2008;36(1):70-80.
- [4] Kohane DS, Langer R. Biocompatibility and drug delivery systems. *Chem Sci* 2010;1(4):441-6. <https://pubs.rsc.org/en/content/articlelanding/2010/sc/c0sc00203h#!div>
- [5] Meng E, Sheybani R. Insight: implantable medical devices. *Lab Chip* 2014;14(17):3233-40.
- [6] Onuki Y, Bhardwaj U, Papadimitrakopoulos F, et al. A review of the biocompatibility of implantable devices: current challenges to overcome foreign body response. *J Diabetes Sci Technol* 2008;2(6):1003-15.
- [7] Coleman K, Dai X, Deng X, et al. 9 - Medical device biocompatibility evaluation: an industry perspective. *Biocompatibility and Performance of Medical Devices* Woodhead Publishing Series in Biomaterials 2012: p. 201-26, 227e. [http:// dx.doi.org /10.1533 / 9780857096456.2.201](http://dx.doi.org/10.1533/9780857096456.2.201)
- [8] Goud NS. Biocompatibility evaluation of medical devices. In book: *A Comprehensive Guide to Toxicology in Nonclinical Drug Development 2017*: p. 825-40. <https://www.sciencedirect.com/science/article/pii/B9780128036204000311>
- [9] Rogers WJ. The effects of sterilization on medical materials and welded devices. In: *Joining and Assembly of Medical Materials and Devices*. Elsevier Ltd., 2013:79-130. <https://www.sciencedirect.com/science/article/pii/B9781845695774500041>
- [10] Yaneva-Deliverska M, Deliversky J, Lyapina M. Biocompatibility of medical devices – legal regulations in the European Union. *J IMAB - Annu Proceeding (Scientific Pap 2015;21(1):705-8*. [https://www.journal-imab- bg.org/issues 2015/issue1 / vol21issue1p705 - 708.html](https://www.journal-imab-bg.org/issues/2015/issue1/vol21issue1p705-708.html)
- [11] Williams DF. Regulatory biocompatibility requirements for biomaterials used in regenerative medicine. *J Mater Sci Mater Med* 2015;26(2):89.